Sanofi: positive data in atopic dermatitis

(CercleFinance.com) - Sanofi has announced that results from a phase IIa study showed that amlitelimab - a monoclonal antibody targeting a key immune system regulator (OX40L) - significantly improved the signs and symptoms of moderate-to-severe atopic dermatitis with a good safety profile.


Prof. Stephan Weidinger, Deputy Director and Professor at the Department of Dermatology and Allergy at the University Hospital of Schleswig-Holstein, called the preliminary results "exciting" and said he looked forward to confirming the data in future clinical trials.

Sanofi says that amlitelimab therefore has the potential to become the first anti-OX40-ligand monoclonal antibody in its therapeutic class for adults with moderate-to-severe atopic dermatitis.

The Sanofi share is down a fraction this afternoon, in a flat market in Paris.


Copyright (c) 2021 CercleFinance.com. All rights reserved.